-
NK cells combined with CD38 antibody to treat multiple myeloma
Time of Update: 2021-08-12
Recent popular reports from Yimaike ★Dry goodsCAR-T therapy shows great power, and the cellular immune industry welcomes market opportunities ★The most potential drug transporter-exosomes Yimai New Observation Click on the picture and register now July 7, 2021 Japan/MedClub News/--XNK Therapeutics recently announced that the Phase II clinical study of its autologous natural killer (NK) cell therapy candidate CellProtect has been included in the first patient.
-
The CD38 monoclonal antibody daratumumab helps patients with multiple myeloma rejuvenate during medical insurance
Time of Update: 2021-08-10
Daratumumab single-drug or combination regimen for the treatment of patients with relapsed or refractory MM has been unanimously recommended by many authoritative guidelines such as NCCN3 in the United States, ESMO4 in Europe, MAYO5 in the United States, and guidelines for the diagnosis and treatment of multiple myeloma in China6 .
-
Express reduces the risk of disease progression by 37%, Janssen’s CD38 antibody combination is approved for second-line treatment of multiple myeloma
Time of Update: 2021-08-09
"Reference: [1] Janssen Announces US FDA Approval of DARZALEX FASPRO® (daratumumab) and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse.
-
New medicine for myeloma! Sanofi CD38 Antibody Sarclisa Combination Therapy Phase III Clinically Significantly Prolonged ProgressIon Survival, Deep Remission!
Time of Update: 2020-06-17
, June 10, 2020 / BIOON/Sanofi has announced positive results from a clinical trial of CD38-targeted antibody drug Sarclisa (isatumab) for recurrent and/or refractable multiple myeloma (MM) PHASE I
-
New drug for multiple myeloma! Sanofi CD38 antibody Sarclisa approved by the European Union, sword
Time of Update: 2020-06-05
04 June 2020 / Biovalley BIOON / -- Sanofi recently announced that the European Commission (EC) has approved the CD38 target antibody drug Sarclisa (isatuximab), combined with Pomadomide and Dexa
-
Treatment of multiple myeloma Sanofi CD38 antibody combination therapy reaches phase 3 clinical end
Time of Update: 2020-05-30
MM is a blood cancer caused by plasma cell cancer in the bone marrow Abnormal plasma cells accumulate in the bone marrow and produce tumors in multiple bones in the body Not only do these cells not fu
-
New myeloma drug! Sanofi CD38 Antibody Sarclisa Phase II Phase II trial pre-empts Johnson and Johnson's $3 billion drug Darzalex
Time of Update: 2020-05-13
2020 May 13 News / BioValley BIOON / - Sanofi (Sanofi) today announced that assess CD38 targeting antibody drug Sarclisa (isatuximab) treatment IKEMA a recurrence of clinical trials and / or ref
-
The world's first monoclonal antibody for the treatment of multiple myeloma CD38 has been approved for marketing in China
Time of Update: 2019-07-05
Today (July 5), the State Food and Drug Administration (SFDA) announced that the State Food and Drug Administration (SFDA) has recently approved the daratumumab injection conditionally Application for
-
Ash2014: anti-CD38 monoclonal antibody will be used to treat multiple myeloma
Time of Update: 2014-12-17
Source: on December 17, 2014, at the 56th Annual Meeting of the American Society of Hematology (ash), Dr Thomas Martin from the University of California, San Francisco, said that anti-CD38 mAb could b